Doctors watch for blood clot risks in Kids' cancer treatment
NCT ID NCT07071051
Summary
This study aims to understand how a leukemia drug called calaspargase pegol affects the blood's ability to clot in children and young adults. Researchers will observe 15 patients aged 2-21 who are already scheduled to receive this drug as part of their standard cancer treatment. By taking blood samples and reviewing medical records, they hope to learn about potential clotting risks to make future treatments safer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.